← Back to Search

Monoclonal Antibodies

Nimacimab for Gastroparesis

Phase 2
Waitlist Available
Research Sponsored by Bird Rock Bio, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 3, day 8, day 10, day 38

Summary

This trial is testing a new medication called nimacimab to see if it can help people with diabetes who have stomach problems. The study focuses on patients whose stomachs take too long to empty, a condition known as diabetic gastroparesis. Researchers want to find out if nimacimab can improve their symptoms and how the body handles the medication.

Eligible Conditions
  • Gastroparesis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 3, day 8, day 10, day 38
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 3, day 8, day 10, day 38 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Nimacimab serum concentration
Other study objectives
Change from baseline in American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary (GCSI-DD) Composite Score at 15 days
Gastric emptying half-time as measured by gamma scans (scintigraphy) after ingestion of a radio-labeled meal.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: NimacimabExperimental Treatment1 Intervention
2.5 mg/kg
Group II: PlaceboPlacebo Group1 Intervention
0.9% sodium chloride

Find a Location

Who is running the clinical trial?

Bird Rock Bio, Inc.Lead Sponsor
2 Previous Clinical Trials
84 Total Patients Enrolled
~1 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top